|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US6881557B2
(en)
*
|
2001-07-12 |
2005-04-19 |
Arrowsmith Technologies Llp |
Super humanized antibodies
|
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
|
US6875433B2
(en)
*
|
2002-08-23 |
2005-04-05 |
The United States Of America As Represented By The Secretary Of The Army |
Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
|
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
AU2004205684A1
(en)
*
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
|
UA115960C2
(uk)
*
|
2003-07-15 |
2018-01-25 |
Емджен, Інк., |
Людські анти-ngf нейтралізуючі антитіла як селективні інгібітори метаболічних шляхів фактора росту нервової тканини (ngf)
|
|
CN100415765C
(zh)
*
|
2003-08-07 |
2008-09-03 |
宜康公司 |
兔单克隆抗体的人源化方法
|
|
EP1660534A2
(en)
*
|
2003-08-22 |
2006-05-31 |
MedImmune, Inc. |
Humanization of antibodies
|
|
US7046714B2
(en)
*
|
2003-09-10 |
2006-05-16 |
Intel Corporation |
Method and apparatus for Raman ring resonator based laser/wavelength converter
|
|
BRPI0416262B1
(pt)
*
|
2003-11-05 |
2022-04-12 |
Roche Glycart Ag |
Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
|
|
EP1697417A2
(en)
*
|
2003-11-07 |
2006-09-06 |
Curagen Corporation |
Antibodies against secretory leukocyte protease inhibitor
|
|
AR046833A1
(es)
|
2003-11-10 |
2005-12-28 |
Schering Corp |
Anticuerpos anti-interleuquina-10
|
|
AU2005207003C1
(en)
|
2004-01-20 |
2013-06-13 |
Humanigen, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
|
WO2005079479A2
(en)
*
|
2004-02-17 |
2005-09-01 |
Absalus, Inc. |
Super-humanized antibodies against respiratory syncytial virus
|
|
AU2005229457B2
(en)
|
2004-03-30 |
2010-11-25 |
Glaxo Group Limited |
Immunoglobulins
|
|
MXPA06011199A
(es)
|
2004-03-31 |
2007-04-16 |
Genentech Inc |
Anticuerpos anti-tgf-beta humanizados.
|
|
WO2005112564A2
(en)
*
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
|
EP1802333A2
(en)
*
|
2004-09-13 |
2007-07-04 |
Arrowsmith Technologies LLP |
Antibody buffering of a ligand in vivo
|
|
WO2006029459A1
(en)
*
|
2004-09-13 |
2006-03-23 |
Evogenix, Inc |
Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof
|
|
AU2005306502B2
(en)
|
2004-11-16 |
2012-11-15 |
Humanigen, Inc. |
Immunoglobulin variable region cassette exchange
|
|
AU2005322869B2
(en)
|
2004-12-30 |
2011-05-12 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Framework residue substituted humanized COL-1 antibodies and their use
|
|
PT1871805T
(pt)
*
|
2005-02-07 |
2019-12-02 |
Roche Glycart Ag |
Moléculas de ligação a antigénios que se ligam ao rfce, vetores que as codificam e as suas utilizações
|
|
JP2008531060A
(ja)
*
|
2005-03-04 |
2008-08-14 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
相補性決定残基の合理的改変を介して免疫グロブリン可変領域をヒト化する方法
|
|
WO2006100582A1
(en)
*
|
2005-03-25 |
2006-09-28 |
Glycart Biotechnology Ag |
Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
|
|
EP1888649A2
(en)
*
|
2005-05-09 |
2008-02-20 |
GlycArt Biotechnology AG |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
|
KR101607288B1
(ko)
|
2005-07-01 |
2016-04-05 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
SI1912675T1
(sl)
*
|
2005-07-25 |
2014-07-31 |
Emergent Product Development Seattle, Llc |
zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
|
|
KR20080068004A
(ko)
*
|
2005-08-15 |
2008-07-22 |
아라나 테라퓨틱스 리미티드 |
뉴 월드 영장류 구조형성영역을 가진 조작 항체
|
|
KR101460932B1
(ko)
*
|
2005-08-26 |
2014-11-12 |
로슈 글리카트 아게 |
변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
|
|
GB0525662D0
(en)
|
2005-12-16 |
2006-01-25 |
Glaxo Group Ltd |
Immunoglobulins
|
|
JP2009519983A
(ja)
*
|
2005-12-20 |
2009-05-21 |
アラーナ・テラピューティクス・リミテッド |
部分的な新世界ザル結合領域を有するキメラ抗体
|
|
WO2007087673A1
(en)
*
|
2006-02-01 |
2007-08-09 |
Arana Therapeutics Limited |
Domain antibody construct
|
|
CA2647449C
(en)
|
2006-03-27 |
2017-05-16 |
Medimmune Limited |
Binding member for gm-csf receptor
|
|
ES2514495T3
(es)
|
2006-05-25 |
2014-10-28 |
Glaxo Group Limited |
Anticuerpos humanizados modificados anti-interleucina-18
|
|
PL2027156T3
(pl)
*
|
2006-06-02 |
2011-06-30 |
Aveo Pharmaceuticals Inc |
Białka wiążące czynnik wzrostowy hapatocytów (HGF)
|
|
AR061170A1
(es)
|
2006-06-02 |
2008-08-06 |
Aveo Pharmaceuticals Inc |
Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
|
|
EP2418223A3
(en)
*
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
ES2506065T3
(es)
|
2006-08-11 |
2014-10-13 |
Csl Limited |
Tratamiento de estados patológicos pulmonares
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
PL2068922T3
(pl)
|
2006-10-19 |
2012-11-30 |
Csl Ltd |
Przeciwciała anty-IL-13R alfa1 i ich zastosowania
|
|
ES2410886T3
(es)
*
|
2006-10-26 |
2013-07-03 |
Janssen Biotech, Inc. |
Métodos para la adaptación al ser humano de anticuerpos monoclonales
|
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
|
NZ578064A
(en)
*
|
2006-12-01 |
2012-01-12 |
Medarex Inc |
Human antibodies that bind cd22 and uses thereof
|
|
US20080139790A1
(en)
*
|
2006-12-08 |
2008-06-12 |
Jennings Philip A |
Chimeric antibodies
|
|
BRPI0720565A2
(pt)
|
2006-12-20 |
2013-09-17 |
Mmr Information Systems Inc |
anticorpos e mÉtodos para a sua preparaÇço e seu uso
|
|
AR065368A1
(es)
|
2007-02-15 |
2009-06-03 |
Astrazeneca Ab |
Anticuerpos para moleculas de ige
|
|
US20100291024A1
(en)
*
|
2007-03-30 |
2010-11-18 |
Xuebin Qin |
Methods and compositions for the treatment of proliferative and pathogenic diseases
|
|
WO2008137066A1
(en)
*
|
2007-05-02 |
2008-11-13 |
The Board Of Regents Of The University Of Oklahoma |
Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
|
|
AR066913A1
(es)
*
|
2007-06-08 |
2009-09-23 |
Irm Llc |
Metodos y composiciones para inducir la apoptosis en celulas cancerosas
|
|
CL2008002085A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
|
|
EP2641618A3
(en)
*
|
2007-07-16 |
2013-10-23 |
Genentech, Inc. |
Humanized anti-CD79B antibodies and immunoconjugates and methods of use
|
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
|
US8748356B2
(en)
*
|
2007-10-19 |
2014-06-10 |
Janssen Biotech, Inc. |
Methods for use in human-adapting monoclonal antibodies
|
|
WO2009072660A1
(ja)
*
|
2007-12-03 |
2009-06-11 |
Kabushiki Kaisya Advance |
抗体作製方法
|
|
AR070141A1
(es)
*
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
|
CN104650230A
(zh)
|
2008-01-31 |
2015-05-27 |
健泰科生物技术公司 |
抗cd79b抗体和免疫偶联物及使用方法
|
|
SG189772A1
(en)
|
2008-04-11 |
2013-05-31 |
Trubion Pharmaceuticals Inc |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
CN102177178B
(zh)
|
2008-08-14 |
2015-07-01 |
梯瓦制药澳大利亚私人有限公司 |
抗il-12/il-23抗体
|
|
NZ591098A
(en)
|
2008-08-20 |
2012-08-31 |
Centocor Ortho Biotech Inc |
Engineered anti-il-13 antibodies, compositions, methods and uses
|
|
WO2010039900A2
(en)
|
2008-09-30 |
2010-04-08 |
Aliva Biopharmaceuticals, Inc. |
Non-human mammals for the production of chimeric antibodies
|
|
JP2012505654A
(ja)
*
|
2008-10-14 |
2012-03-08 |
ヤンセン バイオテツク，インコーポレーテツド |
抗体をヒト化及び親和性成熟する方法
|
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
|
MX2011000455A
(es)
|
2008-11-07 |
2011-02-25 |
Galaxy Biotech Llc |
Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.
|
|
BRPI0921006A2
(pt)
*
|
2008-11-13 |
2015-12-15 |
Emergent Product Dev Seattle |
terapias imunoterapêuticas combinadas de cd37 e usos destas
|
|
TW201029662A
(en)
|
2008-12-19 |
2010-08-16 |
Glaxo Group Ltd |
Novel antigen binding proteins
|
|
NZ594668A
(en)
*
|
2009-03-16 |
2012-10-26 |
Cephalon Australia Pty Ltd |
Humanised antibodies with anti-tumour activity
|
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
WO2011022472A2
(en)
*
|
2009-08-18 |
2011-02-24 |
President And Fellows Of Harvard College |
Methods and compositions for the treatment of proliferative and pathogenic diseases
|
|
CA2778552A1
(en)
*
|
2009-11-05 |
2011-05-12 |
Cephalon Australia Pty Ltd |
Treatment of cancer involving mutated kras or braf genes
|
|
CA2776513C
(en)
|
2009-11-24 |
2017-08-01 |
Alethia Biotherapeutics Inc. |
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
|
|
MY172472A
(en)
|
2009-12-10 |
2019-11-26 |
Regeneron Pharma |
Mice that make heavy chain antibodies
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
PH12012501308A1
(en)
|
2009-12-23 |
2013-01-21 |
4 Antibody Ag |
Binding members for human cytomegalovirus
|
|
UY33202A
(es)
|
2010-01-28 |
2011-08-31 |
Glaxo Group Ltd |
Proteínas de unión a cd127
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
ES2547142T5
(es)
|
2010-02-08 |
2021-12-09 |
Regeneron Pharma |
Cadena ligera común de ratón
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
WO2011106697A1
(en)
|
2010-02-25 |
2011-09-01 |
Schepens Eye Research Institute |
Therapeutic compositions for the treatment of dry eye disease
|
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
|
KR20210010942A
(ko)
|
2010-03-31 |
2021-01-28 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
|
SG184473A1
(en)
*
|
2010-04-07 |
2012-11-29 |
Abbvie Inc |
Tnf-alpha binding proteins
|
|
WO2011127324A2
(en)
|
2010-04-08 |
2011-10-13 |
JN Biosciences, LLC |
Antibodies to cd122
|
|
ES2566602T3
(es)
|
2010-04-09 |
2016-04-14 |
Aveo Pharmaceuticals, Inc. |
Anticuerpos anti-ErbB3
|
|
TW201210612A
(en)
|
2010-06-03 |
2012-03-16 |
Glaxo Group Ltd |
Humanised antigen binding proteins
|
|
WO2011156617A2
(en)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anti-egfr antibodies
|
|
WO2012003472A1
(en)
|
2010-07-02 |
2012-01-05 |
Aveo Pharmaceuticals, Inc. |
Anti-notch1 antibodies
|
|
CA2804399A1
(en)
|
2010-07-06 |
2012-01-12 |
Aveo Pharmaceuticals, Inc. |
Anti-ron antibodies
|
|
US9127057B2
(en)
|
2010-07-20 |
2015-09-08 |
Teva Pharmaceuticals Ausralia Pty Ltd |
Anti-IL-23 heterodimer specific antibodies
|
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
|
EP3192880B1
(en)
|
2010-08-18 |
2019-10-09 |
Fred Hutchinson Cancer Research Center |
Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd)
|
|
US8916695B2
(en)
*
|
2010-11-23 |
2014-12-23 |
Glaxo Group Limited |
Antigen binding proteins to oncostatin M (OSM)
|
|
CA2819038C
(en)
|
2010-12-06 |
2023-10-17 |
Seattle Genetics, Inc. |
Humanized antibodies to liv-1 and use of same to treat cancer
|
|
AU2011347354A1
(en)
|
2010-12-20 |
2013-08-01 |
Medimmune Limited |
Anti-IL-18 antibodies and their uses
|
|
BR112013016235B1
(pt)
|
2010-12-22 |
2020-03-31 |
Cephalon Australia Pty Ltd |
Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
AU2011352205B2
(en)
*
|
2010-12-31 |
2016-06-16 |
Bioatla, Llc |
Express humanization of antibodies
|
|
CA3027071A1
(en)
|
2011-01-14 |
2013-07-19 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
ES2666550T3
(es)
|
2011-04-19 |
2018-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos
|
|
WO2012175735A1
(en)
|
2011-06-23 |
2012-12-27 |
Vib Vzw |
A20 inhibitors for the treatment of respiratory viral infections
|
|
US8663637B2
(en)
|
2011-08-05 |
2014-03-04 |
Research Development Foundation |
Methods and compositions for modulation of Olfml3 mediated angiogenesis
|
|
IL273982B2
(en)
|
2011-08-05 |
2023-03-01 |
Regeneron Pharma |
Humanized mice possess a universal light chain
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
JP2014531210A
(ja)
|
2011-09-30 |
2014-11-27 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
ＴＬ１ａに対する抗体およびその使用
|
|
CA2851322C
(en)
|
2011-10-10 |
2020-03-31 |
Medimmune Limited |
Treatment for rheumatoid arthritis with gm csfr alpha antibodies
|
|
CN107880123A
(zh)
|
2011-10-28 |
2018-04-06 |
普罗典娜生物科学有限公司 |
识别α‑突触核蛋白的人源化抗体
|
|
KR102096224B1
(ko)
|
2011-10-28 |
2020-04-03 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
폴리펩티드 구축물 및 이의 용도
|
|
AU2012327878A1
(en)
|
2011-10-28 |
2014-05-29 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
|
NZ626269A
(en)
|
2011-12-20 |
2016-06-24 |
Janssen Biotech Inc |
Anti-phf-tau antibodies and their uses
|
|
EP2793949B1
(en)
|
2011-12-23 |
2018-08-22 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
US20150011431A1
(en)
|
2012-01-09 |
2015-01-08 |
The Scripps Research Institute |
Humanized antibodies
|
|
AU2013211874B2
(en)
|
2012-01-27 |
2017-11-02 |
Prothena Biosciences Limited |
Humanized antibodies that recognize alpha-synuclein
|
|
US9546219B2
(en)
|
2012-02-08 |
2017-01-17 |
North Carolina State University |
Treatment of allergic diseases with recombinant antibodies
|
|
WO2013125221A1
(ja)
*
|
2012-02-21 |
2013-08-29 |
静岡県 |
抗体精製用アフィニティリガンド
|
|
MX2014010164A
(es)
|
2012-02-22 |
2014-11-25 |
Alethia Biotherapeutics Inc |
Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
|
|
EP2847219A1
(en)
|
2012-05-07 |
2015-03-18 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
RU2014153674A
(ru)
*
|
2012-06-05 |
2016-07-27 |
Регенерон Фармасьютикалз, Инк. |
Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
|
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
CA2876284A1
(en)
|
2012-07-05 |
2014-01-09 |
Glaxo Group Limited |
Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
|
|
EP2872894B1
(en)
|
2012-07-13 |
2019-04-17 |
Innate Pharma |
Screening of conjugated antibodies
|
|
WO2014018625A1
(en)
|
2012-07-25 |
2014-01-30 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
WO2014060444A1
(en)
|
2012-10-15 |
2014-04-24 |
Medimmune Limited |
Antibodies to amyloid beta
|
|
CA2888345C
(en)
|
2012-10-24 |
2020-04-21 |
Research Development Foundation |
Jam-c antibodies and methods for treatment of cancer
|
|
CA2889765C
(en)
|
2012-10-26 |
2021-06-22 |
Minna D. BALBAS |
Androgen receptor variants and methods for making and using
|
|
MX2015005757A
(es)
|
2012-11-08 |
2015-11-18 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
|
|
EP2916872B1
(en)
|
2012-11-09 |
2019-02-27 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
EP2935330B1
(en)
|
2012-12-19 |
2019-04-24 |
Aveo Pharmaceuticals, Inc. |
Anti-notch3 antibodies
|
|
CN105073133B
(zh)
|
2012-12-21 |
2021-04-20 |
Aveo制药公司 |
抗gdf15抗体
|
|
EP3530284B1
(en)
|
2012-12-26 |
2023-10-25 |
OncoSynergy, Inc. |
Anti-integrin beta1 antibody compositions and methods of use thereof
|
|
MX2015009901A
(es)
|
2013-02-01 |
2016-04-06 |
Santa Maria Biotherapeutics Inc |
Administración de un compuesto de antiactivina a a un sujeto.
|
|
PT2951208T
(pt)
|
2013-02-01 |
2019-12-30 |
Univ California |
Anticorpos anti-cd83 e sua utilização
|
|
SG11201505762XA
(en)
|
2013-02-07 |
2015-08-28 |
Csl Ltd |
Il-11r binding proteins and uses thereof
|
|
AU2014249458A1
(en)
|
2013-03-11 |
2015-09-24 |
Amgen Inc. |
Protein formulations
|
|
RU2708314C2
(ru)
|
2013-03-11 |
2019-12-05 |
Джензим Корпорейшн |
Гипергликозилированные связывающие полипептиды
|
|
CA2902026C
(en)
|
2013-03-13 |
2023-08-29 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
EP2968582B1
(en)
|
2013-03-15 |
2020-07-01 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
|
WO2014143886A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Edimer Pharmaceuticals, Inc. |
Anti-ectodysplasin antibodies
|
|
EP2970483A2
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Inc. |
Methods and compositions relating to anti-ccr7 antigen binding proteins
|
|
MD20180107A2
(ro)
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
EP2992013B1
(en)
|
2013-04-29 |
2019-12-04 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
WO2014202773A1
(en)
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
CA2914189C
(en)
|
2013-06-21 |
2023-03-14 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
KR20160022370A
(ko)
*
|
2013-06-24 |
2016-02-29 |
넥스이뮨 |
면역요법을 위한 조성물 및 방법
|
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
WO2015004633A1
(en)
|
2013-07-12 |
2015-01-15 |
Neotope Biosciences Limited |
Antibodies that recognize islet-amyloid polypeptide (iapp)
|
|
US9850302B2
(en)
|
2013-07-12 |
2017-12-26 |
Prothena Biosciences Limited |
Antibodies that recognize IAPP
|
|
CN111518199A
(zh)
*
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
|
AU2014308699C1
(en)
|
2013-08-21 |
2022-06-02 |
Board Of Regents, The University Of Texas System |
Compositions and methods for targeting connexin hemichannels
|
|
DK3041513T3
(da)
|
2013-09-08 |
2020-10-26 |
Kodiak Sciences Inc |
Zwitterioniske faktor viii-polymerkonjugater
|
|
PL3065774T3
(pl)
|
2013-11-06 |
2021-12-13 |
Janssen Biotech, Inc |
Przeciwciała anty-ccl17
|
|
WO2015075635A2
(en)
|
2013-11-19 |
2015-05-28 |
Prothena Biosciences Limited |
Monitoring immunotherapy of lewy body disease from constipation symptoms
|
|
KR102339724B1
(ko)
|
2013-11-28 |
2021-12-17 |
씨에스엘 리미티드 |
신장병증의 치료 방법
|
|
US9321834B2
(en)
|
2013-12-05 |
2016-04-26 |
Leidos, Inc. |
Anti-malarial compositions
|
|
CA2933590C
(en)
|
2013-12-11 |
2023-10-03 |
Sloan-Kettering Institute For Cancer Research |
Glucocorticoid inhibitors for treatment of prostate cancer
|
|
DK3082860T3
(da)
|
2013-12-18 |
2021-01-25 |
Csl Ltd |
Fremgangsmåde til behandling af sår
|
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
|
|
CA2938933A1
(en)
|
2014-03-12 |
2015-09-17 |
Prothena Biosciences Limited |
Anti-laminin4 antibodies specific for lg4-5
|
|
DK3116911T3
(da)
|
2014-03-12 |
2019-09-30 |
Prothena Biosciences Ltd |
Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
|
|
JP2017512772A
(ja)
|
2014-03-12 |
2017-05-25 |
プロセナ バイオサイエンシーズ リミテッド |
Ｌｇ１〜３に特異的な抗ラミニン４抗体
|
|
WO2015136468A1
(en)
|
2014-03-13 |
2015-09-17 |
Prothena Biosciences Limited |
Combination treatment for multiple sclerosis
|
|
EP3129067B1
(en)
|
2014-03-19 |
2023-01-04 |
Genzyme Corporation |
Site-specific glycoengineering of targeting moieties
|
|
BR112016021572A2
(pt)
|
2014-03-21 |
2017-10-03 |
Regeneron Pharma |
Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
|
|
CA2944402A1
(en)
|
2014-04-08 |
2015-10-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
|
US10087259B1
(en)
|
2014-04-28 |
2018-10-02 |
Memorial Sloan Kettering Cancer Center |
Depleting tumor-specific tregs
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
WO2015179435A1
(en)
|
2014-05-19 |
2015-11-26 |
Bayer Healthcare Llc |
Optimized humanized monoclonal antibodies against activated protein c and uses thereof
|
|
TW202132337A
(zh)
|
2014-05-28 |
2021-09-01 |
美商艾吉納斯公司 |
抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法
|
|
EP3157953B1
(en)
|
2014-06-20 |
2021-12-22 |
Aveo Pharmaceuticals, Inc. |
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
|
|
US20170137505A1
(en)
|
2014-06-20 |
2017-05-18 |
Aveo Pharmaceuticals, Inc. |
Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
|
CN107073297B
(zh)
|
2014-07-08 |
2021-09-14 |
纽约大学 |
Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
|
|
AU2015286604B2
(en)
|
2014-07-10 |
2019-08-15 |
Hd Immune Gmbh |
Substances and methods for the use in prevention and/or treatment in Huntington's disease
|
|
CN114099671A
(zh)
|
2014-08-12 |
2022-03-01 |
鳄鱼生物科学公司 |
利用抗cd40抗体的组合疗法
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
CA2961917A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
|
EP3262071B8
(en)
|
2014-09-23 |
2022-05-18 |
F. Hoffmann-La Roche AG |
Method of using anti-cd79b immunoconjugates
|
|
US20170306008A1
(en)
|
2014-09-25 |
2017-10-26 |
Aveo Pharmaceuticals, Inc. |
Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
KR102210104B1
(ko)
|
2014-10-17 |
2021-02-01 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
CA2965170A1
(en)
|
2014-10-23 |
2016-04-28 |
Dendrocyte Biotech Pty Ltd |
Cd83 binding proteins and uses thereof
|
|
JP6829194B2
(ja)
*
|
2014-10-24 |
2021-02-10 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｖｈ−ｖｌドメイン間角度に基づく抗体ヒト化の方法
|
|
UA125637C2
(uk)
|
2014-10-29 |
2022-05-11 |
Тева Фармасьютікалз Острейліа Пті Лтд |
ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
|
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
JP2017537084A
(ja)
|
2014-11-12 |
2017-12-14 |
トラコン ファーマシューティカルズ、インコーポレイテッド |
抗エンドグリン抗体及びその用途
|
|
ES2717308T3
(es)
|
2014-12-06 |
2019-06-20 |
Gemoab Monoclonals Gmbh |
Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
|
|
CA2967224C
(en)
|
2014-12-11 |
2023-08-22 |
Inbiomotion S.L. |
Binding members for human c-maf
|
|
US10940212B2
(en)
|
2014-12-19 |
2021-03-09 |
Monash University |
IL-21 agonist antibodies and methods of treatment using same
|
|
EP3970748B1
(en)
|
2014-12-24 |
2024-07-24 |
NexImmune, Inc. |
Nanoparticle compositions and methods for immunotherapy
|
|
HK1245154A1
(zh)
|
2014-12-30 |
2018-08-24 |
细胞基因公司 |
抗cd47抗体及其用途
|
|
TWI786505B
(zh)
|
2015-01-28 |
2022-12-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
TWI711631B
(zh)
|
2015-01-28 |
2020-12-01 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
TWI718121B
(zh)
|
2015-01-28 |
2021-02-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
|
ES2929614T3
(es)
|
2015-03-17 |
2022-11-30 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos anti-MUC16 y usos de los mismos
|
|
CA2976740A1
(en)
|
2015-03-18 |
2016-09-22 |
Seattle Genetics, Inc. |
Cd48 antibodies and conjugates thereof
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
DK3277725T3
(da)
|
2015-03-30 |
2021-01-11 |
Regeneron Pharma |
Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
|
|
EP3286214B1
(en)
|
2015-04-24 |
2023-12-06 |
The Regents of the University of California |
Modulators of ror1-ror2 binding
|
|
AU2016255768B2
(en)
|
2015-04-29 |
2022-03-10 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
|
TWI716405B
(zh)
|
2015-05-07 |
2021-01-21 |
美商艾吉納斯公司 |
抗ox40抗體及其使用方法
|
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
|
SI3303394T1
(sl)
|
2015-05-29 |
2020-10-30 |
Agenus Inc. |
Protitelesa proti-CTLA-4 in postopki njihove uporabe
|
|
TW201709932A
(zh)
|
2015-06-12 |
2017-03-16 |
西雅圖遺傳學公司 |
Ｃｄ１２３抗體及其共軛物
|
|
BR112017027498A2
(pt)
|
2015-06-30 |
2018-09-11 |
Seattle Genetics Inc |
anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
|
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
|
US10669343B2
(en)
|
2015-08-05 |
2020-06-02 |
Janssen Biotech, Inc. |
Anti-CD154 antibodies and methods of using them
|
|
EP3334761B1
(en)
|
2015-08-13 |
2023-07-19 |
New York University |
Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
|
JP6913078B2
(ja)
|
2015-08-13 |
2021-08-04 |
ニューヨーク・ユニバーシティ |
タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
|
|
CN107949573B
(zh)
|
2015-09-01 |
2022-05-03 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
WO2017041004A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for modulating t-cell mediated immune response
|
|
EP3349791A1
(en)
|
2015-09-15 |
2018-07-25 |
Board of Regents, The University of Texas System |
T-cell receptor (tcr)-binding antibodies and uses thereof
|
|
JP2018530540A
(ja)
|
2015-09-16 |
2018-10-18 |
プロセナ バイオサイエンシーズ リミテッド |
巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用
|
|
WO2017046774A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
|
UA126278C2
(uk)
|
2015-09-21 |
2022-09-14 |
Аптево Рісьорч Енд Девелопмент Ллс |
Поліпептиди, які зв'язують cd3
|
|
CA2997444A1
(en)
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Asgr inhibitors for reducing cholesterol levels
|
|
KR102791773B1
(ko)
|
2015-10-30 |
2025-04-03 |
갤럭시 바이오테크, 엘엘씨 |
사멸 수용체 4 및 사멸 수용체 5에 결합하는 매우 강력한 항체
|
|
MY198562A
(en)
|
2015-11-03 |
2023-09-05 |
Janssen Biotech Inc |
Antibodies specifically binding pd-1 and their uses
|
|
BR112018010766A8
(pt)
|
2015-11-27 |
2019-02-26 |
Csl Ltd |
proteínas de ligação ao cd131 e usos das mesmas
|
|
WO2017096017A1
(en)
|
2015-12-02 |
2017-06-08 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
|
WO2017100670A1
(en)
|
2015-12-09 |
2017-06-15 |
Corvus Pharmaceuticals, Inc. |
Humanized anti-cd73 antibodies
|
|
BR112018012344A2
(pt)
|
2015-12-17 |
2018-12-04 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a hla-dr e seus usos
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
AU2017206656B2
(en)
|
2016-01-10 |
2024-02-01 |
Neotx Therapeutics Ltd. |
Immunopotentiator enhanced superantigen mediated cancer immunotherapy
|
|
HK1259075A1
(zh)
|
2016-02-17 |
2019-11-22 |
Seattle Genetics, Inc. |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
CA3015839A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Regents Of The University Of Texas System |
Connexin (cx)43 hemichannel-binding antibodies and uses thereof
|
|
WO2017149513A1
(en)
|
2016-03-03 |
2017-09-08 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
|
IL261188B
(en)
|
2016-03-04 |
2022-08-01 |
Jn Biosciences Llc |
An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
|
|
WO2017153953A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
|
WO2017153955A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
|
WO2017158064A1
(en)
|
2016-03-15 |
2017-09-21 |
Astrazeneca Ab |
Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
|
|
CN109071637B
(zh)
|
2016-03-23 |
2022-03-22 |
首尔大学校产学协力团 |
结合严重发热伴血小板减少综合征病毒的包膜糖蛋白的抗体及其用途
|
|
RU2744959C2
(ru)
|
2016-03-23 |
2021-03-17 |
Мэбспейс Байосайнсиз (Сучжоу) Ко., Лтд |
Новые анти-pd-l1 антитела
|
|
JP7241541B2
(ja)
|
2016-03-29 |
2023-03-17 |
エスティーキューブ，インコーポレイテッド |
グリコシル化ｐｄ－ｌ１に特異的な二重機能抗体およびその使用方法
|
|
JP7572146B2
(ja)
|
2016-03-29 |
2024-10-23 |
エスティーキューブ アンド カンパニー，インコーポレイテッド |
グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法
|
|
US10603380B2
(en)
|
2016-04-01 |
2020-03-31 |
Kite Pharma, Inc. |
Chimeric antigen and T cell receptors and methods of use
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
DK3436030T3
(da)
|
2016-04-01 |
2022-11-21 |
Kite Pharma Inc |
Kimæriske receptorer og fremgangsmåder til anvendelse deraf
|
|
TWI761831B
(zh)
|
2016-04-01 |
2022-04-21 |
美商凱特製藥公司 |
嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途
|
|
US11016085B2
(en)
|
2016-04-25 |
2021-05-25 |
The Johns Hopkins University |
ZNT8 assays for drug development and pharmaceutical compositions
|
|
PE20190208A1
(es)
|
2016-05-02 |
2019-02-07 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau
|
|
EP3452508A1
(en)
|
2016-05-02 |
2019-03-13 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
US10752679B2
(en)
|
2016-05-02 |
2020-08-25 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
TWI895621B
(zh)
|
2016-05-27 |
2025-09-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
MY194619A
(en)
|
2016-06-02 |
2022-12-07 |
Abbvie Inc |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
|
WO2017208210A1
(en)
|
2016-06-03 |
2017-12-07 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
|
KR102522419B1
(ko)
|
2016-06-06 |
2023-04-17 |
시티 오브 호프 |
Baff-r 표적 키메라 항원 수용체-변형된 t 세포 및 그 용도
|
|
EP4628094A2
(en)
|
2016-06-06 |
2025-10-08 |
City of Hope |
Baff-r antibodies and uses thereof
|
|
WO2018007924A2
(en)
|
2016-07-02 |
2018-01-11 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
EP3478714A2
(en)
|
2016-07-02 |
2019-05-08 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
|
JP7016470B2
(ja)
|
2016-07-02 |
2022-02-07 |
プロセナ バイオサイエンシーズ リミテッド |
抗トランスサイレチン抗体
|
|
AU2017292752B2
(en)
|
2016-07-06 |
2023-07-27 |
Celgene Corporation |
Antibodies with low immunogenicity and uses thereof
|
|
CN109689685A
(zh)
|
2016-07-08 |
2019-04-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体及其使用方法
|
|
US10793636B2
(en)
|
2016-07-11 |
2020-10-06 |
Corvus Pharmaceuticals, Inc. |
Anti-CD73 antibodies
|
|
US10501775B2
(en)
|
2016-07-12 |
2019-12-10 |
Kite Pharma, Inc. |
Antigen binding molecules and methods of use thereof
|
|
MA56165A
(fr)
|
2016-07-12 |
2022-04-20 |
H Lundbeck As |
Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
|
|
CN109689690B
(zh)
|
2016-07-15 |
2023-10-03 |
武田药品工业株式会社 |
用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
|
|
US11618784B2
(en)
|
2016-07-19 |
2023-04-04 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-CD47 combination therapy
|
|
EP3487883B1
(en)
|
2016-07-20 |
2023-01-04 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
|
|
EP3493834A1
(en)
|
2016-08-07 |
2019-06-12 |
Novartis AG |
Mrna-mediated immunization methods
|
|
CA3033665A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
SG11201900746RA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
CA3034105A1
(en)
|
2016-09-23 |
2018-03-29 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
EP4538295A3
(en)
|
2016-09-28 |
2025-06-18 |
Kite Pharma, Inc. |
Antigen binding molecules and methods of use thereof
|
|
KR102576042B1
(ko)
|
2016-10-11 |
2023-09-07 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
WO2018089335A1
(en)
|
2016-11-09 |
2018-05-17 |
North Carolina State University |
Treatment of allergic diseases with chimeric protein
|
|
US10889635B2
(en)
|
2016-11-15 |
2021-01-12 |
H. Lundbeck A/S |
Agents, uses and methods for the treatment of synucleinopathy
|
|
EP3544612A4
(en)
|
2016-11-23 |
2020-05-13 |
Acetylon Pharmaceuticals, Inc. |
PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
|
|
JOP20170192A1
(ar)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
|
IL266918B2
(en)
|
2016-12-07 |
2024-03-01 |
Agenus Inc |
Anti-ctla-4 antibodies and methods of use thereof
|
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
|
CN110072888B
(zh)
|
2016-12-16 |
2023-07-18 |
H.隆德贝克有限公司 |
药剂、用途和方法
|
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
|
CN110267985B
(zh)
|
2017-01-04 |
2023-05-23 |
H.隆德贝克有限公司 |
用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
|
|
ES2900233T3
(es)
|
2017-02-14 |
2022-03-16 |
Kite Pharma Inc |
Moléculas que se unen a CD70 y métodos de uso de las mismas
|
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
|
EP4095161A1
(en)
|
2017-03-15 |
2022-11-30 |
Tsinghua University |
Novel anti-trkb antibodies
|
|
JOP20180021A1
(ar)
|
2017-03-16 |
2019-01-30 |
Janssen Biotech Inc |
الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
|
|
CA3057841A1
(en)
|
2017-03-27 |
2018-10-04 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
|
PL3601367T3
(pl)
|
2017-03-30 |
2025-03-31 |
The University Of Queensland |
Cząsteczki chimeryczne i ich zastosowania
|
|
CA3059366A1
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
|
EP3610010A4
(en)
|
2017-04-14 |
2021-02-24 |
Kodiak Sciences Inc. |
COMPLEMENT FACTOR-D-ANTAGONIST-ANTIBODIES AND CONJUGATES THEREOF
|
|
MA50958A
(fr)
|
2017-04-21 |
2020-10-14 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
MX2019013045A
(es)
|
2017-05-02 |
2020-02-12 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau.
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
JP7366755B2
(ja)
|
2017-05-30 |
2023-10-23 |
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ |
抗ダブルコルチン様キナーゼ１抗体および使用方法
|
|
KR102692379B1
(ko)
|
2017-06-05 |
2024-08-05 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 사용 방법
|
|
US11578371B2
(en)
|
2017-06-15 |
2023-02-14 |
Mira Dx, Inc. |
Biomarkers for predicting tumor response to and toxicity of immunotherapy
|
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
|
WO2020159504A1
(en)
|
2019-01-30 |
2020-08-06 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
|
JP2020528936A
(ja)
|
2017-07-27 |
2020-10-01 |
ノモキャン ファーマシューティカルズ エルエルシー |
Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用
|
|
EP3625254B1
(en)
|
2017-07-31 |
2023-12-13 |
F. Hoffmann-La Roche AG |
Three-dimensional structure-based humanization method
|
|
KR20240138135A
(ko)
|
2017-08-25 |
2024-09-20 |
파이브 프라임 테라퓨틱스, 인크. |
B7-h4 항체 및 그의 사용 방법
|
|
IL273202B2
(en)
|
2017-09-11 |
2024-08-01 |
Univ Monash |
Binding proteins to the human thrombin receptor, par4
|
|
US11464784B2
(en)
|
2017-09-15 |
2022-10-11 |
The Regents Of The University Of California |
Inhibition of aminocylase 3 (AA3) in the treatment of cancer
|
|
KR20230052312A
(ko)
|
2017-09-15 |
2023-04-19 |
카이트 파마 인코포레이티드 |
관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템
|
|
CN111492246A
(zh)
|
2017-09-20 |
2020-08-04 |
梅尔莎纳医疗公司 |
用于预测对napi2b靶向疗法的响应的组合物和方法
|
|
WO2019060713A1
(en)
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
ANTIGEN-BINDING MOLECULES AND METHODS OF USE THEREOF
|
|
US20200290978A1
(en)
|
2017-09-26 |
2020-09-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
AU2017434556B2
(en)
|
2017-09-28 |
2024-11-14 |
F. Hoffmann-La Roche Ag |
Dosing regimes for treatment of synucleinopathies
|
|
MX2020003043A
(es)
|
2017-10-06 |
2020-10-05 |
Prothena Biosciences Ltd |
Métodos para detectar transtiretina.
|
|
WO2019084427A1
(en)
|
2017-10-27 |
2019-05-02 |
Kite Pharma, Inc. |
T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
|
|
MX2020004512A
(es)
|
2017-10-31 |
2020-08-13 |
|
Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos.
|
|
EP3710471A1
(en)
|
2017-11-16 |
2020-09-23 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
|
CN111433223B
(zh)
|
2017-11-29 |
2024-08-27 |
诺和诺德A/S（股份有限公司） |
抗甲状腺素运载蛋白单克隆抗体的冻干制剂
|
|
US20200283540A1
(en)
|
2017-12-01 |
2020-09-10 |
Seattle Genetics, Inc. |
Humanized anti-liv1 antibodies for the treatment of breast cancer
|
|
US11180552B2
(en)
|
2017-12-01 |
2021-11-23 |
Seagen Inc. |
CD47 antibodies and uses thereof for treating cancer
|
|
BR112020010694A2
(pt)
|
2017-12-01 |
2020-11-10 |
Abbvie Inc. |
agonista de receptor de glicocorticoides e imunoconjugados do mesmo
|
|
CA3088199A1
(en)
|
2018-01-12 |
2019-07-18 |
Takeda Pharmaceutical Company Limited |
Subcutaneous dosing of anti-cd38 antibodies
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019152895A1
(en)
|
2018-02-01 |
2019-08-08 |
Memorial Sloan Kettering Cancer Center |
Antibodies to galectin-3 and methods of use thereof
|
|
US20200377609A1
(en)
|
2018-02-14 |
2020-12-03 |
Kite Pharma, Inc. |
Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
|
|
SG11202007820QA
(en)
|
2018-02-21 |
2020-09-29 |
Five Prime Therapeutics Inc |
B7-h4 antibody dosing regimens
|
|
KR20200123170A
(ko)
|
2018-02-21 |
2020-10-28 |
파이브 프라임 테라퓨틱스, 인크. |
B7-h4 항체 제형
|
|
FI3756009T3
(fi)
|
2018-02-23 |
2023-12-01 |
Meso Scale Technologies Llc |
Menetelmiä antigeeniä sitovien molekyylien seulontaan normalisoimalla antigeeniä sitovan molekyylin pitoisuus
|
|
MA52416A
(fr)
|
2018-03-02 |
2021-04-21 |
Five Prime Therapeutics Inc |
Anticorps b7-h4 et leurs procédés d'utilisation
|
|
MX2020009152A
(es)
|
2018-03-02 |
2020-11-09 |
Kodiak Sciences Inc |
Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
|
|
EA202092088A1
(ru)
|
2018-03-05 |
2020-11-13 |
Янссен Фармацевтика Нв |
Антитела анти-phf-тау и их применение
|
|
AU2019234468A1
(en)
|
2018-03-12 |
2020-10-01 |
Memorial Sloan Kettering Cancer Center |
Bispecific binding agents and uses thereof
|
|
WO2019183437A1
(en)
|
2018-03-23 |
2019-09-26 |
North Carolina State University |
Methods and compositions for antibody to high affinity receptor for ige
|
|
MA52777A
(fr)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech Inc |
Agents de liaison psma et utilisations correspondantes
|
|
SMT202500221T1
(it)
|
2018-05-24 |
2025-07-22 |
Janssen Biotech Inc |
Anticorpi anti-cd3 e usi di essi
|
|
JP2021524255A
(ja)
|
2018-05-24 |
2021-09-13 |
ヤンセン バイオテツク，インコーポレーテツド |
単一特異性及び二重特異性抗体抗−ｔｍｅｆｆ２抗体並びにそれらの使用
|
|
TW202519270A
(zh)
|
2018-06-07 |
2025-05-16 |
美商思進公司 |
喜樹鹼結合物
|
|
US12006357B2
(en)
|
2018-06-26 |
2024-06-11 |
Mor Research Applications Ltd. |
Transthyretin antibodies and uses thereof
|
|
PE20211091A1
(es)
|
2018-07-02 |
2021-06-14 |
Amgen Inc |
Proteina de union al antigeno anti-steap1
|
|
CA3107463A1
(en)
|
2018-07-24 |
2020-01-30 |
Medimmune, Llc |
Antibody directed against s. aureus clumping factor a (clfa)
|
|
US12103968B2
(en)
|
2018-08-16 |
2024-10-01 |
The Johns Hopkins University |
Antibodies to human ZnT8
|
|
WO2020037215A1
(en)
|
2018-08-17 |
2020-02-20 |
Icahn School Of Medicine At Mount Sinai |
Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
|
|
WO2020037225A1
(en)
|
2018-08-17 |
2020-02-20 |
Mersana Therapeutics, Inc. |
Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof
|
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
|
JP7459075B2
(ja)
|
2018-10-09 |
2024-04-01 |
メディミューン，エルエルシー |
スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体
|
|
CN113164602A
(zh)
|
2018-10-09 |
2021-07-23 |
免疫医疗有限责任公司 |
抗金黄色葡萄球菌抗体的组合
|
|
CN113166242B
(zh)
|
2018-10-15 |
2024-11-19 |
戊瑞治疗有限公司 |
用于癌症的组合疗法
|
|
UA129124C2
(uk)
|
2018-11-08 |
2025-01-22 |
Протена Біосайєнсіс Лімітед |
Антитіла, що розпізнають тау
|
|
EP3817773B1
(en)
|
2018-11-26 |
2024-07-24 |
Forty Seven, Inc. |
Humanized antibodies against c-kit
|
|
JP2022510634A
(ja)
|
2018-11-28 |
2022-01-27 |
フォーティ セブン， インコーポレイテッド |
除去レジメンに抵抗性の遺伝的に改変されたｈｓｐｃ
|
|
CN113412117B
(zh)
|
2018-12-12 |
2025-03-04 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
AR117735A1
(es)
*
|
2018-12-25 |
2021-08-25 |
Joint Stock Company Biocad |
ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
JP7565607B2
(ja)
|
2019-01-28 |
2024-10-11 |
メイプル バイオテック エルエルシー |
肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト
|
|
WO2020163225A1
(en)
|
2019-02-05 |
2020-08-13 |
Seattle Genetics, Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
|
BR112021016984A2
(pt)
|
2019-03-01 |
2021-11-30 |
Allogene Therapeutics Inc |
Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
|
|
AU2020231366A1
(en)
|
2019-03-03 |
2021-08-12 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
CN113811544A
(zh)
|
2019-03-13 |
2021-12-17 |
免疫医疗有限责任公司 |
减少定殖患者中的金黄色葡萄球菌感染
|
|
CA3135032A1
(en)
|
2019-04-03 |
2020-10-08 |
Genzyme Corporation |
Anti-alpha beta tcr binding polypeptides with reduced fragmentation
|
|
WO2020210650A1
(en)
|
2019-04-12 |
2020-10-15 |
Medimmune, Llc |
Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
|
|
US11732041B2
(en)
|
2019-04-19 |
2023-08-22 |
Allogene Therapeutics, Inc. |
Antibodies against 4G7-derived chimeric antigen receptors
|
|
AR118720A1
(es)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
|
US20220243197A1
(en)
|
2019-04-30 |
2022-08-04 |
Gigagen, Inc. |
Recombinant Polyclonal Proteins and Methods of Use Thereof
|
|
AU2020275142A1
(en)
|
2019-05-15 |
2021-12-16 |
Neotx Therapeutics Ltd. |
Cancer treatment
|
|
CN115867291A
(zh)
|
2019-05-22 |
2023-03-28 |
麻省理工学院 |
环状rna组合物和方法
|
|
US20220227888A1
(en)
|
2019-06-07 |
2022-07-21 |
Amgen Inc. |
Bispecific binding constructs with selectively cleavable linkers
|
|
US11781248B2
(en)
|
2019-06-13 |
2023-10-10 |
Allogene Therapeutics, Inc. |
Anti-TALEN antibodies and uses thereof
|
|
JP2022536975A
(ja)
|
2019-06-21 |
2022-08-22 |
カイト ファーマ インコーポレイテッド |
ＴＧＦ－β受容体及び使用方法
|
|
AU2020318975A1
(en)
|
2019-07-22 |
2022-03-17 |
Seagen Inc. |
Humanized anti-LIV1 antibodies for the treatment of cancer
|
|
CA3147735A1
(en)
|
2019-07-26 |
2021-02-04 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
|
WO2021042019A1
(en)
|
2019-08-30 |
2021-03-04 |
Agenus Inc. |
Anti-cd96 antibodies and methods of use thereof
|
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
|
US12366570B2
(en)
|
2019-10-01 |
2025-07-22 |
The Johns Hopkins University |
Cell-based ZNT8 assay
|
|
EP4038101A2
(en)
|
2019-10-04 |
2022-08-10 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates
|
|
JP2022552282A
(ja)
|
2019-10-09 |
2022-12-15 |
エスティーキューブ アンド カンパニー |
グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法
|
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
|
EP4048696A1
(en)
|
2019-10-23 |
2022-08-31 |
Kite Pharma, Inc. |
Anti-idiotypic antigen binding molecules and methods of use thereof
|
|
PH12022551208A1
(en)
|
2019-11-18 |
2023-04-24 |
Janssen Biotech Inc |
Vaccines based on mutant calr and jak2 and their uses
|
|
TWI877278B
(zh)
|
2019-12-30 |
2025-03-21 |
美商思進公司 |
以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
|
|
CA3164168A1
(en)
|
2020-01-08 |
2021-07-15 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
|
US20230138520A1
(en)
*
|
2020-01-16 |
2023-05-04 |
Caerus Therapeutics, Inc. |
Humanized antibodies specific for myeloma and ovarian cancer cells
|
|
CA3165319A1
(en)
|
2020-01-31 |
2021-08-05 |
Vincent K. Tuohy |
Anti-mullerian hormone receptor 2 antibodies and methods of use
|
|
IL295515A
(en)
|
2020-02-12 |
2022-10-01 |
Janssen Pharmaceutica Nv |
Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
IL295188A
(en)
|
2020-02-18 |
2022-09-01 |
Alector Llc |
Pilra antibodies and methods of use thereof
|
|
KR20240096884A
(ko)
|
2020-03-10 |
2024-06-26 |
매사추세츠 인스티튜트 오브 테크놀로지 |
조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
|
|
CA3173981A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
|
PE20240020A1
(es)
|
2020-03-13 |
2024-01-04 |
Janssen Biotech Inc |
Materiales y metodos para la union de siglec-3/cd33
|
|
MX2022011591A
(es)
|
2020-03-18 |
2023-03-06 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos anti-ceramida.
|
|
IL296387B2
(en)
|
2020-03-19 |
2024-08-01 |
Avidity Biosciences Inc |
Preparations and methods for the treatment of facial, back and arm muscle atrophy
|
|
WO2021186398A1
(en)
|
2020-03-19 |
2021-09-23 |
Medimmune Limited |
Anti-klebsiella pneumoniae antibodies and uses thereof
|
|
KR20230069042A
(ko)
|
2020-03-20 |
2023-05-18 |
오나 테라퓨틱스, 인코포레이티드 |
원형 rna 조성물 및 방법
|
|
HRP20240182T1
(hr)
|
2020-03-26 |
2024-04-26 |
Vanderbilt University |
Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
|
|
EP4126952A1
(en)
|
2020-03-26 |
2023-02-08 |
Seagen Inc. |
Methods of treating multiple myeloma
|
|
MX2022011880A
(es)
|
2020-03-27 |
2022-10-20 |
Avidity Biosciences Inc |
Composiciones y metodos para tratar distrofia muscular.
|
|
JP7772715B2
(ja)
|
2020-04-17 |
2025-11-18 |
ニューヨーク・ユニバーシティ |
治療用ｍｕｓｋ抗体
|
|
CA3182150A1
(en)
|
2020-05-17 |
2021-11-25 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
|
WO2021236855A1
(en)
|
2020-05-19 |
2021-11-25 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
JP2023528350A
(ja)
|
2020-05-27 |
2023-07-04 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用
|
|
AR122493A1
(es)
|
2020-06-02 |
2022-09-14 |
Arcus Biosciences Inc |
Anticuerpos anti-tigit
|
|
US20230203198A1
(en)
|
2020-06-04 |
2023-06-29 |
Amgen Inc. |
Bispecific binding constructs
|
|
CA3177152A1
(en)
|
2020-06-12 |
2021-12-16 |
David Scott Johnson |
Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
|
|
KR20230026489A
(ko)
|
2020-06-24 |
2023-02-24 |
프로테나 바이오사이언시즈 리미티드 |
소르틸린을 인지하는 항체
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
CN116507636A
(zh)
|
2020-07-20 |
2023-07-28 |
阿斯利康(英国)有限公司 |
SARS-CoV-2蛋白、抗SARS-CoV-2抗体以及它们的使用方法
|
|
AU2021317111A1
(en)
|
2020-07-29 |
2023-03-30 |
Janssen Biotech, Inc. |
Proteins comprising HLA-G antigen binding domains and their uses
|
|
WO2022031834A1
(en)
|
2020-08-05 |
2022-02-10 |
Gigagen, Inc. |
Recombinant polyclonal proteins targeting zika and methods of use thereof
|
|
US11484604B2
(en)
|
2020-08-07 |
2022-11-01 |
Fortis Therapeutics, Inc. |
Immunoconjugates targeting CD46 and methods of use thereof
|
|
CN116234577A
(zh)
|
2020-08-10 |
2023-06-06 |
阿斯利康(英国)有限公司 |
用于治疗和预防covid-19的sars-cov-2抗体
|
|
US20220047677A1
(en)
|
2020-08-14 |
2022-02-17 |
Kite Pharma, Inc. |
Immune cell function
|
|
WO2022040482A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
CA3192254A1
(en)
|
2020-08-21 |
2022-02-24 |
Shanghai GenBase Biotechnology Co., Ltd. |
Antibody specifically bound to glycosylated ceacam5
|
|
EP4501951A3
(en)
|
2020-08-25 |
2025-04-30 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
KR20230078657A
(ko)
|
2020-08-27 |
2023-06-02 |
에노시 테라퓨틱스 코퍼레이션 |
자가면역 질환 및 암을 치료하기 위한 방법 및 조성물
|
|
AU2021349385A1
(en)
|
2020-09-28 |
2023-05-25 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
|
CA3198590A1
(en)
|
2020-10-13 |
2022-04-21 |
Rajkumar Ganesan |
Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
|
|
AU2021393456A1
(en)
|
2020-12-03 |
2023-06-29 |
Amgen Inc. |
Immunoglobuline constructs with multiple binding domains
|
|
US12404315B2
(en)
|
2020-12-21 |
2025-09-02 |
Allogene Therapeutics, Inc. |
Protease-activating CD45-gate CAR
|
|
EP4267623A1
(en)
|
2020-12-24 |
2023-11-01 |
Kite Pharma, Inc. |
Prostate cancer chimeric antigen receptors
|
|
PE20240761A1
(es)
|
2021-01-28 |
2024-04-17 |
Janssen Biotech Inc |
Proteinas de union a psma y usos de estas
|
|
KR20230135593A
(ko)
|
2021-01-28 |
2023-09-25 |
알로젠 테라퓨틱스 인코포레이티드 |
면역 세포를 형질도입하는 방법
|
|
EP4284918A1
(en)
|
2021-01-29 |
2023-12-06 |
Allogene Therapeutics, Inc. |
Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
|
|
US12180521B2
(en)
|
2021-02-19 |
2024-12-31 |
Theripion, Inc. |
Paraoxonase fusion polypeptides and related compositions and methods
|
|
WO2022187663A1
(en)
|
2021-03-04 |
2022-09-09 |
Allogene Therapeutics, Inc. |
Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
|
|
US12454563B2
(en)
|
2021-03-11 |
2025-10-28 |
Kite Pharma, Inc. |
Immune cell function
|
|
TW202304986A
(zh)
|
2021-03-24 |
2023-02-01 |
美商健生生物科技公司 |
靶向cd22及cd79b的抗體
|
|
KR20230160353A
(ko)
|
2021-03-24 |
2023-11-23 |
얀센 바이오테크 인코포레이티드 |
Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
|
|
JP2024513172A
(ja)
|
2021-03-26 |
2024-03-22 |
ヤンセン バイオテツク，インコーポレーテツド |
対らせん状細線維タウに対するヒト化抗体及びその使用
|
|
EP4323399A4
(en)
|
2021-04-14 |
2025-04-09 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
IL307384A
(en)
|
2021-04-16 |
2023-11-01 |
Kite Pharma Inc |
Molecules with a dual link to TACI and BCMA
|
|
CN117677633A
(zh)
|
2021-05-24 |
2024-03-08 |
凯德药业股份有限公司 |
基于nkg2d的嵌合抗原受体
|
|
WO2022251311A1
(en)
|
2021-05-25 |
2022-12-01 |
Seagen Inc. |
Methods of quantifying anti-cd40 antibodies
|
|
CN113393899A
(zh)
*
|
2021-05-26 |
2021-09-14 |
江苏普瑞康生物医药科技有限公司 |
基于动态规划的抗体人源化的方法与装置
|
|
KR20240019811A
(ko)
|
2021-06-08 |
2024-02-14 |
카이트 파마 인코포레이티드 |
Gpc3 결합 분자
|
|
CA3219932A1
(en)
|
2021-06-10 |
2022-12-15 |
Robert Alexander WESSELHOEFT |
Circular rna compositions and methods
|
|
EP4355776A1
(en)
|
2021-06-14 |
2024-04-24 |
Argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
|
JP2024526090A
(ja)
|
2021-06-15 |
2024-07-17 |
アロジーン セラピューティクス，インコーポレイテッド |
同種ｃａｒ ｔ細胞の持続性を延長するための宿主ｃｄ７０＋アロ反応性細胞の選択的標的化
|
|
US20240287199A1
(en)
|
2021-06-18 |
2024-08-29 |
Alligator Bioscience Ab |
Novel combination therapies and uses thereof
|
|
US20240279360A1
(en)
|
2021-06-23 |
2024-08-22 |
Lycia Therapeutics, Inc. |
Bifunctional compounds containing igf-2 polypeptides
|
|
TW202317190A
(zh)
|
2021-06-29 |
2023-05-01 |
美商思進公司 |
以非岩藻糖基化抗ｃｄ７０抗體及ｃｄ４７拮抗劑之組合治療癌症之方法
|
|
CA3225542A1
(en)
|
2021-07-01 |
2023-01-05 |
Denali Therapeutics Inc. |
Oligonucleotide conjugates targeted to the transferrin receptor
|
|
JP2024524614A
(ja)
|
2021-07-14 |
2024-07-05 |
ライシア セラピューティクス， インコーポレイテッド |
Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート
|
|
EP4370156A1
(en)
|
2021-07-14 |
2024-05-22 |
Lycia Therapeutics, Inc. |
M6pr cell surface receptor binding compounds and conjugates
|
|
WO2023009989A1
(en)
|
2021-07-26 |
2023-02-02 |
Kite Pharma, Inc. |
Split chimeric antigen receptors and methods of use
|
|
EP4388008A1
(en)
|
2021-08-16 |
2024-06-26 |
Hemogenyx Pharmaceuticals Llc |
Anti-flt3 antibodies, cars, car t cells and methods of use
|
|
WO2023023489A2
(en)
|
2021-08-17 |
2023-02-23 |
Hemogenyx Pharmaceuticals Llc |
Bispecific anti-flt3/cd3 antibodies and methods of use
|
|
WO2023023607A1
(en)
|
2021-08-20 |
2023-02-23 |
The Johns Hopkins University |
Cell-surface antibody to a specific biomarker of pancreatic beta-cells
|
|
MX2024002281A
(es)
|
2021-08-23 |
2024-05-20 |
Immunitas Therapeutics Inc |
Anticuerpos anti-cd161 y usos de los mismos.
|
|
PE20240727A1
(es)
|
2021-08-27 |
2024-04-15 |
Janssen Biotech Inc |
Anticuerpos anti-psma y usos de estos
|
|
JPWO2023032955A1
(es)
|
2021-08-31 |
2023-03-09 |
|
|
|
KR20240055874A
(ko)
|
2021-09-16 |
2024-04-29 |
어비디티 바이오사이언시스 인크. |
안면견갑상완 근이영양증을 치료하는 조성물 및 방법
|
|
TW202327650A
(zh)
|
2021-09-23 |
2023-07-16 |
美商思進公司 |
治療多發性骨髓瘤之方法
|
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
|
AU2022353839A1
(en)
|
2021-09-30 |
2024-05-02 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
EP4408478A1
(en)
|
2021-09-30 |
2024-08-07 |
Seagen Inc. |
B7-h4 antibody-drug conjugates for the treatment of cancer
|
|
AR127745A1
(es)
|
2021-10-18 |
2024-02-28 |
Kite Pharma Inc |
Dominios de señalización para receptores quiméricos de antígenos
|
|
US20250297030A1
(en)
*
|
2021-10-21 |
2025-09-25 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Anti-muc17 nanobody and use thereof
|
|
JP2024541961A
(ja)
|
2021-10-27 |
2024-11-13 |
ヴィルトゥオーソ ビンコ，インク． |
Ｃｄ４７に関連する疾患を処置するための多特異性抗体
|
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防ｃｏｖｉｄ—１９之組成物
|
|
EP4430024A1
(en)
|
2021-11-08 |
2024-09-18 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
EP4460330A1
(en)
|
2022-01-06 |
2024-11-13 |
Virtuoso Binco, Inc. |
Conjugates, compositions and methods of use
|
|
WO2023152581A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Method of treating cancer with psmaxcd3 antibody
|
|
TW202342510A
(zh)
|
2022-02-18 |
2023-11-01 |
英商Ｒｑ生物科技有限公司 |
抗體
|
|
MX2024010339A
(es)
|
2022-02-23 |
2024-09-30 |
Xencor Inc |
Anticuerpos anti-cd28 x anti-psma.
|
|
AU2023244350A1
(en)
|
2022-03-29 |
2024-09-05 |
Allogene Therapeutics Inc. |
Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
|
|
IL316221A
(en)
|
2022-04-12 |
2024-12-01 |
Minerva Biotechnologies Corp |
Anti-MUC1* variant antibodies and their uses
|
|
CA3256096A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
ANTIBODIES AGAINST SARS-CoV-2 AND THEIR METHODS OF USE
|
|
WO2023218099A1
(en)
|
2022-05-13 |
2023-11-16 |
argenx BV |
In utero treatment of a fetus having genetic disease/neuromuscular disease
|
|
AU2022463987A1
(en)
|
2022-06-23 |
2025-01-09 |
Alligator Bioscience Ab |
Combination therapies
|
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
|
GB202210957D0
(en)
|
2022-07-27 |
2022-09-07 |
Alligator Bioscience Ab |
Novel dosages
|
|
GB202210965D0
(en)
|
2022-07-27 |
2022-09-07 |
Alligator Bioscience Ab |
Novel dosages
|
|
CN119497721A
(zh)
|
2022-07-29 |
2025-02-21 |
艾莱克特有限责任公司 |
转铁蛋白受体抗原结合结构域及其用途
|
|
AU2023316021A1
(en)
|
2022-07-29 |
2025-03-06 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2024026445A1
(en)
|
2022-07-29 |
2024-02-01 |
Allogene Therapeutics Inc. |
Engineered cells with reduced gene expression to mitigate immune cell recognition
|
|
EP4577234A1
(en)
|
2022-08-26 |
2025-07-02 |
Kite Pharma, Inc. |
Improving immune cell function
|
|
EP4567818A4
(en)
*
|
2022-09-09 |
2025-12-17 |
Nanjing Genscript Biotech Co Ltd |
METHOD FOR DESIGNING A SEQUENCE OF HUMANIZED ANTIBODY
|
|
EP4590708A2
(en)
|
2022-09-19 |
2025-07-30 |
Allogene Therapeutics, Inc. |
B-cell maturation antigen (bcma) anti-idiotypic antibodies
|
|
GB202215115D0
(en)
|
2022-10-13 |
2022-11-30 |
Univ Nottingham |
VEGF antibodies
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
CN120417937A
(zh)
|
2022-11-17 |
2025-08-01 |
赛诺菲 |
Ceacam5抗体-药物缀合物及其使用方法
|
|
TW202440623A
(zh)
|
2022-11-28 |
2024-10-16 |
美商艾洛基因醫療公司 |
靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
|
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
EP4634235A1
(en)
|
2022-12-14 |
2025-10-22 |
Allogene Therapeutics, Inc. |
Cd70 anti-idiotype antibodies
|
|
AU2023398825A1
(en)
|
2022-12-15 |
2025-06-26 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
EP4651901A1
(en)
|
2023-01-18 |
2025-11-26 |
Lycia Therapeutics, Inc. |
Cycling lysosomal targeting antibody conjugates
|
|
WO2024155748A1
(en)
|
2023-01-18 |
2024-07-25 |
Lycia Therapeutics, Inc. |
M6pr binding compounds and conjugates
|
|
WO2024155747A2
(en)
|
2023-01-18 |
2024-07-25 |
Lycia Therapeutics, Inc. |
Asgpr binding compounds and conjugates
|
|
EP4406973A1
(en)
|
2023-01-27 |
2024-07-31 |
Fundació Privada Institut de Recerca de la SIDA-Caixa |
Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
|
|
US20240261406A1
(en)
|
2023-02-02 |
2024-08-08 |
Minerva Biotechnologies Corporation |
Chimeric antigen receptor compositions and methods for treating muc1* diseases
|
|
CN120769864A
(zh)
|
2023-03-09 |
2025-10-10 |
凯德药业股份有限公司 |
抗原结合分子和使用方法
|
|
KR20250173600A
(ko)
|
2023-03-17 |
2025-12-10 |
옥시토프 파마 비.브이. |
항-포스포콜린 항체 및 그 사용 방법
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
AU2024271522A1
(en)
|
2023-05-15 |
2025-11-20 |
argenx BV |
Antibodies for use in agrin-deficient disorders
|
|
WO2024263710A1
(en)
|
2023-06-20 |
2024-12-26 |
Allogene Therapeutics, Inc. |
Methods of detection for engineered cells
|
|
WO2025038736A1
(en)
|
2023-08-15 |
2025-02-20 |
Gigagen, Inc. |
Methods of analyzing recombinant polyclonal proteins
|
|
WO2025038732A1
(en)
|
2023-08-15 |
2025-02-20 |
Gigagen, Inc. |
Recombinant polyclonal proteins targeting hepatitis b virus (hbv) and methods of use thereof
|
|
TW202515919A
(zh)
|
2023-09-01 |
2025-04-16 |
比利時商艾托斯比利時公司 |
抗ｔｒｅｍ２抗體及使用方法
|
|
TW202530252A
(zh)
|
2023-09-15 |
2025-08-01 |
愛爾蘭商普羅希那生物科學有限公司 |
降低抗體免疫原性及改良抗體穩定性之組成物及方法
|
|
WO2025076389A1
(en)
|
2023-10-06 |
2025-04-10 |
Seagen Inc. |
Methods of treating advanced solid tumors with b7-h4 antibody-drug conjugates
|
|
WO2025080693A1
(en)
|
2023-10-11 |
2025-04-17 |
Minerva Biotechnologies Corporation |
Anti-muc1* antibody drug complexes and uses thereof
|
|
TW202515903A
(zh)
|
2023-10-12 |
2025-04-16 |
瑞士商百濟神州瑞士有限責任公司 |
手術前後基於抗ｐｄ－１之治療
|
|
WO2025096560A1
(en)
|
2023-10-30 |
2025-05-08 |
Allogene Therapeutics, Inc. |
Engineered cells
|
|
WO2025133707A1
(en)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anti-tdp-43 antibodies and uses thereof
|
|
WO2025147575A1
(en)
|
2024-01-06 |
2025-07-10 |
Generate Biomedicines, Inc. |
Anti-il-13 antibodies and methods of use thereof
|
|
WO2025163468A1
(en)
|
2024-01-30 |
2025-08-07 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
WO2025166077A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Compositions comprising progranulin and uses thereof
|
|
WO2025166042A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2025166040A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
|
|
WO2025166045A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
|
|
WO2025171411A1
(en)
|
2024-02-09 |
2025-08-14 |
Herophilus, Inc. |
Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
|
|
US20250262300A1
(en)
|
2024-02-16 |
2025-08-21 |
Kite Pharma, Inc. |
Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
|
|
US20250276074A1
(en)
|
2024-03-01 |
2025-09-04 |
Prelude Therapeutics Incorporated |
Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
|
|
US20250361297A1
(en)
|
2024-03-12 |
2025-11-27 |
Adaptam Therapeutics, S.L. |
Anti- siglec-15 binding molecules and methods of use
|
|
WO2025196639A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody-drug conjugates, and uses thereof
|
|
WO2025248500A1
(en)
|
2024-05-31 |
2025-12-04 |
Janssen Biotech, Inc. |
Antibody drug conjugates that target enpp3
|
|
CN119039446B
(zh)
*
|
2024-10-30 |
2025-01-28 |
首都医科大学宣武医院 |
抗gad65抗体及其应用
|